TWIST Session 5:
Cannabis *(This session will be repeated to allow more participation)*
Tuesday 24th October, 11:30h – 13:00h (Room 1.05) & 14:30h – 16:00h (Room 1.08)

Eva Hoch *PD PhD, leading Psychologist and Head of the Cannabinoid Research Group, Clinic for Psychiatry and Psychotherapy, University of Munich*

Dr Hoch is a psychologist with extensive experience in addiction research, specifically in Cannabis addiction. She created, and has established, the highly effective CANDIS program for treating Cannabis dependence. Due to her varied therapeutic and scientific experience, covering, for example, the running of multi-site randomized-clinical trials or establishing the German guidelines of addiction therapy, she has gained in-depth knowledge of evidence based medicine. Currently, she is heading the CaPRis project, which collates expertise on the risks and potentials of recreational and medical cannabis use on behalf of the German Health Ministry. This has involved a comprehensive systematic literature review and critical data evaluation covering different types of human cannabinoid studies of the last decade.

Chris Maria Friemel *PhD, scientific associate in the CaPRis project, Clinic for Psychiatry and Psychotherapy, University of Munich*
Dr. Friemel is a psychologist and clinical neuroscientist with extensive knowledge in the endocannabinoid system and addiction research. She has primarily worked in the field of basic science investigating the neurobiological role of the endocannabinoid system in reward and addiction, specifically during adolescence. Some of her experimental results have been successfully translated to epidemiological findings of adolescent drug taking behaviour. Extensively trained in the methodology of evidence-based medicine, she is the core scientist of the CaPRis project.

Session Description:

Learning objective(s):
- Overview of European legalization situation for cannabis and treatment options for cannabis addiction
- Newest research data and evaluation of the harms of recreational cannabis use on physical, psychological and psychosocial outcomes
- Newest research data and evaluation of the effectivity, tolerability and safety of cannabinoid treatment for different medical purposes

Scope/main topics covered:
- The session is intended to provide insight into the major outcomes of the comprehensive evaluation of Cannabis-related harms as well the medical efficacy of cannabinoids carried out by the CaPRis project. Covering all relevant work on cannabis and cannabinoids within the last decade, this overview provides the most recent data in the field. In addition, the European situation of cannabis legalization will be outlined and their potential problems will be discussed. An overview of available and newly developed treatment options for cannabis addiction will be given.

Training/Learning formats:
- Presentation with topic-specific discussions

Learning outcome(s) (what should the trainee be able to do following the session?):
- Knowledge of legalization status of Cannabis and Cannabinoids within Europe
- State-of-the-art evaluation of the harms of recreational Cannabis use
- Critical appraisal of benefits and tolerability of medical cannabinoids for various medical indications

Related LxAddictions 2017 sessions:
PS26 (regulation), PS30 (market), SS30 (risky use) and Plenary IV (Kilmer)